---
title: "LifeSci Capital Sticks to Its Buy Rating for IDEAYA Biosciences (IDYA)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295303725.md"
description: "LifeSci Capital analyst Charles Zhu maintained a Buy rating on IDEAYA Biosciences (IDYA) with a $58 price target. Zhu, who covers the Healthcare sector, has a strong track record with a 25.9% average return. The stock currently holds a Strong Buy consensus among analysts, with an average price target of $51.91."
datetime: "2026-08-08T14:35:22.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295303725.md)
  - [en](https://longbridge.com/en/news/295303725.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295303725.md)
generator: "portal-rs"
---

# LifeSci Capital Sticks to Its Buy Rating for IDEAYA Biosciences (IDYA)

LifeSci Capital analyst Charles Zhu maintained a Buy rating on IDEAYA Biosciences today and set a price target of $58.00.

### Claim 55% Off TipRanks

-   Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
-   Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks

Zhu covers the Healthcare sector, focusing on stocks such as Revolution Medicines, Kura Oncology, and IDEAYA Biosciences. According to TipRanks, Zhu has an average return of 25.9% and a 63.60% success rate on recommended stocks. 

IDEAYA Biosciences has an analyst consensus of Strong Buy, with a price target consensus of $51.91.

### Related Stocks

- [IDYA.US](https://longbridge.com/en/quote/IDYA.US.md)
- [RVMD.US](https://longbridge.com/en/quote/RVMD.US.md)
- [KURA.US](https://longbridge.com/en/quote/KURA.US.md)
- [RVMDW.US](https://longbridge.com/en/quote/RVMDW.US.md)

## Related News & Research

- [Wedbush Keeps Their Buy Rating on IDEAYA Biosciences (IDYA)](https://longbridge.com/en/news/296510282.md)
- [IDEAYA Biosciences Announces Clinical Collaboration with Genentech in MTAP-Deleted KRAS G12D-Mutant Pancreatic Cancer | IDYA Stock News](https://longbridge.com/en/news/296337883.md)
- [Alliance Global Partners Reaffirms Their Buy Rating on Pelthos Therapeutics (PTHS)](https://longbridge.com/en/news/296781912.md)
- [Freeport-McMoRan (FCX): New Buy Recommendation for This Basic Materials Giant](https://longbridge.com/en/news/296794439.md)
- [Maxim Group Reaffirms Their Buy Rating on Our Bond Inc (OBAI)](https://longbridge.com/en/news/296798454.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**